Patent

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, May 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

The Coretec Group Announces a Full Utility Patent Filing and Provides an Update on the Definitive Share Exchange Agreement with Core Optics

Retrieved on: 
Thursday, May 2, 2024
CHS, EVS, PCAOB, OTCQB, ANN, Silicon, Engineering, Patent

On May 1, 2024, The Coretec Group filed its full utility patent application for Endurion after filing its provisional patent application in May 2023.

Key Points: 
  • On May 1, 2024, The Coretec Group filed its full utility patent application for Endurion after filing its provisional patent application in May 2023.
  • TAAD is highly qualified in this space, working directly with public companies including those with business operations in Asia.
  • The corporate headcount has also grown, predominantly in manufacturing and engineering, to meet the demand and work through its backlog.
  • The process for this share exchange will take time, and we are appreciative of the patience from employees, partners and especially our shareholders.”

Gevo Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Gevo, GEVO, Agriculture, DOE, Investment, Depreciation, Section, Research, Interest, Natural gas, LG Chem, RNG, Carbon, Engineering, Patent, Face, Inflation, Bank statement, SAF, British thermal unit, Letter, GAAP, Polyethylene

ENGLEWOOD, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter 2024 and recent corporate highlights.

Key Points: 
  • ENGLEWOOD, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter 2024 and recent corporate highlights.
  • Of that amount, approximately $17.1 million was spent in the first quarter of 2024.
  • As a result, we expect to receive $0.8 million in payments under that agreement during the second quarter of 2024.
  • They will review Gevo’s financial results and provide an update on recent corporate highlights.

Trust Stamp announces the allowance of a new patent taking its portfolio of AI-powered patents into data protection applications

Retrieved on: 
Thursday, May 2, 2024
Patent, Trust, Privacy, Legislation, GDPR, Cryptocurrency

Atlanta, GA, May 02, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI) announced that the company has received from USPTO an allowance notification for utility patent #17/719,975 entitled,  “Personal Identifiable Information Encoder”.

Key Points: 
  • Atlanta, GA, May 02, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI) announced that the company has received from USPTO an allowance notification for utility patent #17/719,975 entitled,  “Personal Identifiable Information Encoder”.
  • Gareth N. Genner, Trust Stamp’s CEO commented, “With 20 allowed and issued patents, and another 13 patents provisional or pending, Trust Stamp has built a substantial intellectual property portfolio.
  • This patent addresses the universal need to ensure security against cyber-attacks as well as providing optimized privacy protection by only storing and sharing tokenized personal data.
  • We believe that this patent has particular significance in the context of privacy legislation such as GDPR and data localization and we will be announcing specific implementations to that end.”

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Retrieved on: 
Thursday, May 2, 2024
CRRT, Bangladesh Technical Education Board, NIH, Hemofiltration, Renal replacement therapy, Patent, Patient, Hospice and palliative medicine, Health, KBT, Pharmaceutical industry

This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.

Key Points: 
  • This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
  • This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.
  • "We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis.
  • This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.

Incubate Launches Policy Lab Under New Leadership and Releases IP White Paper

Retrieved on: 
Friday, April 26, 2024
Competition, Medication, World Intellectual Property Day, Policy, Climate, Intellectual property, Innovation, Axelsen, University, Patent, Patient, Incubation, Private sector, Drug development

In the coming months, Incubate Policy Lab -- the research arm of Incubate -- plans to release additional reports and white papers focused on issues at the intersection of policymaking, venture investment, and drug development.

Key Points: 
  • Accompanying the launch is a new white paper examining the important role intellectual property protections play in biopharmaceutical development.
  • "We launched Incubate Policy Lab to explore the various impacts policy decisions can have on innovation and investment in the life sciences industry," said Incubate executive director John Stanford.
  • In the coming months, Incubate Policy Lab -- the research arm of Incubate -- plans to release additional reports and white papers focused on issues at the intersection of policymaking, venture investment, and drug development.
  • "We're delighted to release this new white paper from Incubate Policy Lab," Axelsen said.

RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board

Retrieved on: 
Thursday, April 25, 2024
Corporation, University, Clemson University, Pharmacy, General counsel, Champaign–Urbana metropolitan area, Biology, Business, CBD, Principal, Pharming, Patent, Pharmaceutical industry

to the RS BioTherapeutics Business Advisory Board.

Key Points: 
  • to the RS BioTherapeutics Business Advisory Board.
  • As a member of the Business Advisory Board, Ms. Wright-Mitchell will also serve as fractional General Counsel and Compliance Advisor for RS BioTherapeutics.
  • Commenting on the addition of Ms. Wright-Mitchell to the Business Advisory Board, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “I was fortunate to work with Jane while we were both at AcelRx and am thrilled to have her join our Business Advisory Board.
  • She is registered to practice before the United States Patent and Trademark Office as well as a licensed pharmacist (Illinois).

Breathalyzer Market Booms with Technological Advances; Key to Reducing Alcohol-Related Road Deaths

Retrieved on: 
Thursday, April 25, 2024
Diageo, World Health Organization, Financial News, Partnership, Workplace, Calibration, Growth, Boston Beer Company, UFC, News, DEO, Statistics, OTC, DUI, Guinness, Safety, Collection, Development, EPS, Marketing, Coors, Molson Coors, Accident, Tea, Weather, SAM, AB InBev, Patent, Patient, Fatality, Prohibition, Blood alcohol content, Drinking, Online shopping

Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program. The device allows our clients to autonomously get tested for breath alcohol without the need for our clinic to station a full-time administrator -- its a game changer for us. Our clinic is saving time and money daily with the Breath Logix device deployed in our office. It has quickly become part of our daily routine and work flow process in our clinic.”

Key Points: 
  • With increasing concerns over road safety and stringent legal measures against drunk driving, the demand for breathalyzers has surged globally.
  • Alcohol-impaired driving remains a critical concern worldwide, contributing significantly to road accidents and fatalities.
  • According to the World Health Organization, road traffic injuries caused by alcohol impairment are a major public health problem that account for nearly 1.35 million deaths annually.
  • In the United States alone, about 28% of all traffic-related deaths are attributed to alcohol-impaired driving.

RecycLiCo Secures Additional Patent in India for Key Battery Recycling Processes Including Graphite Separation

Retrieved on: 
Thursday, April 25, 2024
ID4, OTCQB, Graphite, Cobalt, Carbon, Patent, Recycling

The Indian patent follows the form of existing patents previously granted for the same invention in other jurisdictions.

Key Points: 
  • The Indian patent follows the form of existing patents previously granted for the same invention in other jurisdictions.
  • The patent incorporates 18 claims, including separation of cobalt compounds from cathode materials containing carbon and graphite.
  • The Company has five (5) additional patent applications relating to lithium-ion battery recycling processes filed globally.
  • “We are pleased to extend our patent portfolio to include another important emerging market,” said RecycLiCo Chairman Paul Hildebrand.

Cannabix’s Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA

Retrieved on: 
Thursday, April 25, 2024
Weather, Contactless, OTC, DUI, Collection, Calibration, Patent, Patient, Prohibition, Blood alcohol content, Drug

Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program. The device allows our clients to autonomously get tested for breath alcohol without the need for our clinic to station a full-time administrator -- its a game changer for us. Our clinic is saving time and money daily with the Breath Logix device deployed in our office. It has quickly become part of our daily routine and work flow process in our clinic.”

Key Points: 
  • The Company reports that the Breath Logix device has been used daily, collecting over a thousand breath samples autonomously.
  • The device captures user photos to confirm and record identity, and delivers near instantaneous Blood Alcohol Content (BAC) breath results.
  • Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program.
  • The Breath Logix helps organizations save money by deploying an autonomous alcohol screening device which eliminates the need for dedicated alcohol screening administrators using conventional handheld devices.